Qin You, Shen Lin, Lu Fu-rong, Shi Wei, Liu Jian-guo
Department of Integrated Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chin J Integr Med. 2008 Jun;14(2):83-7. doi: 10.1007/s11655-008-0083-7. Epub 2008 Aug 6.
To investigate the effect of Xiaoyu Zhixue Tablet (XYZXT) on the expression of platelet membrane glycoprotein (GP) Ib/IX/V complex and GP I b alpha in patients with chronic renal failure (CRF) in early metaphase.
Fifty-one patients with CRF in early metaphase (treated group) were treated with XYZXT, 3 months as the course of treatment for 2 courses. The previous therapies remained unchanged. Flow cytometry was used to assess the expression of platelet GP Ib/IX/V complex and GP Ib alpha in patients with CRF, and turbidity method was used to determine the platelet maximum aggregation rate (MAR), meanwhile the renal function was measured. The final data were compared with those before the treatment, and with those in the normal control group (31 healthy subjects).
Compared with the normal control group, expressions of GP I b/IX/V complex and GP I b alpha, and platelet MAR in CRF patients were significantly lower (P=0.007, P=0.001, P=0.009) before the treatment; after the treatment with XYZXT, the above indexes in CRF patients were remarkably increased (P=0.033, P=0.026, P=0.045), but still lower than those in the normal control group, however, it was not statistically significant.
(1) The expression of GP I b/IX/V complex in CRF patients of early metaphase was decreased, which lead to platelet aggregation dysfunction. This might be one of the reasons for the hemorrhagic trend in CRF. (2) XYZXT was able to upgrade expressions of GP I b/IX/V complex and GP I b alpha in CRF patients, improve platelet function and down-regulate platelet activation in patients with CRF.
探讨消瘀止血片(XYZXT)对慢性肾衰竭(CRF)早中期患者血小板膜糖蛋白(GP)Ib/IX/V复合物及GP I bα表达的影响。
将51例CRF早中期患者(治疗组)采用XYZXT治疗,以3个月为1个疗程,共治疗2个疗程。既往治疗方案不变。采用流式细胞术检测CRF患者血小板GP Ib/IX/V复合物及GP I bα的表达,采用比浊法测定血小板最大聚集率(MAR),同时检测肾功能。将最终数据与治疗前进行比较,并与正常对照组(31例健康受试者)的数据进行比较。
与正常对照组比较,CRF患者治疗前GP I b/IX/V复合物及GP I bα的表达、血小板MAR均显著降低(P = 0.007、P = 0.001、P = 0.009);经XYZXT治疗后,CRF患者上述指标显著升高(P = 0.033、P = 0.026、P = 0.045),但仍低于正常对照组,差异无统计学意义。
(1)CRF早中期患者GP I b/IX/V复合物表达降低,导致血小板聚集功能障碍。这可能是CRF出血倾向的原因之一。(2)XYZXT能够上调CRF患者GP I b/IX/V复合物及GP I bα的表达,改善血小板功能,下调CRF患者血小板活化。